Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands.
van der Kooij MK, Joosse A, Speetjens FM, Hospers GA, Bisschop C, de Groot JW, Koornstra R, Blank CU, Kapiteijn E. van der Kooij MK, et al. Among authors: joosse a. Acta Oncol. 2017 Jan;56(1):101-103. doi: 10.1080/0284186X.2016.1260773. Epub 2016 Dec 2. Acta Oncol. 2017. PMID: 27911126 No abstract available.
Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study.
van der Kooij MK, Joosse A, Suijkerbuijk KPM, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Boers-Sonderen MJ, van den Eertwegh AJM, de Groot JWB, Haanen JBAG, Hospers GAP, Piersma D, van Rijn RS, van der Veldt AAM, Vreugdenhil G, Westgeest HM, Wouters MWJM, Dekkers OM, Kapiteijn E. van der Kooij MK, et al. Among authors: joosse a. Br J Cancer. 2023 Mar;128(5):707-710. doi: 10.1038/s41416-022-02088-8. Epub 2022 Dec 23. Br J Cancer. 2023. PMID: 36564561 Free PMC article. No abstract available.
Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol.
Janssen JC, van Dijk B, de Joode K, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Boers-Sonderen MJ, van den Eertwegh AJM, de Groot JWB, Jalving M, de Jonge MJA, Joosse A, Kapiteijn E, Kamphuis-Huismans AM, Naipal KAT, Piersma D, Rikhof B, Westgeest HM, Vreugdenhil G, Oomen-de Hoop E, Mulder EEAP, van der Veldt AAM. Janssen JC, et al. Among authors: joosse a. BMC Cancer. 2024 May 23;24(1):632. doi: 10.1186/s12885-024-12336-0. BMC Cancer. 2024. PMID: 38783238 Free PMC article.
Lymph node ratio as a prognostic factor in melanoma: results from European Organization for Research and Treatment of Cancer 18871, 18952, and 18991 studies.
Testori AA, Suciu S, van Akkooi ACJ, Suppa M, Eggermont AMM, de Vries E, Joosse A; European Organization for Research and Treatment of Cancer (EORTC) Melanoma Group. Testori AA, et al. Among authors: joosse a. Melanoma Res. 2018 Jun;28(3):222-229. doi: 10.1097/CMR.0000000000000433. Melanoma Res. 2018. PMID: 29432281
Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment.
Hurkmans DP, Verhoeven JGHP, de Leur K, Boer K, Joosse A, Baan CC, von der Thüsen JH, van Schaik RHN, Mathijssen RHJ, van der Veldt AAM, Hesselink DA. Hurkmans DP, et al. Among authors: joosse a. J Immunother Cancer. 2019 Jul 12;7(1):182. doi: 10.1186/s40425-019-0653-6. J Immunother Cancer. 2019. PMID: 31300068 Free PMC article.
28 results